Cumulative impact of social determinants of health on outcomes after immunotherapy for lung cancer: A real-world analysis.
Abstract
234 Background: Social determinants of health (SDOH) can have deleterious impact on lung cancer outcomes. Individually, SDOH increase progression risk, but their cumulative impact has not been well studied. We examined the combined and cumulative impact of SDOH on lung cancer progression and mortality. Methods: We performed a real-world, retrospective, analysis of a large, certified lung cancer center in Germany. Overall, 288 patients were treated with pembrolizumab monotherapy or pembrolizumab-based combination therapy. We grouped patients by their cumulative adverse SDOH burden: 0, 1, 2, or 3+ factors. SDOH components included lower educational attainment, below-median estimated income, rural residence, long distance to the center, social isolation (not married/not partnered status, divorced/separated status). Cox Proportional Hazards model estimated association between SDOH count and mortality/progression (adjusted for age, gender, ECOG, smoking, stage). Results: Among 288 patients, 34 had 0 adverse SDOH factors, 61 had 1, 84 had 2, and 109 had 3+. A higher SDOH burden was associated with lower income, greater distance to the center and rural residence. In adjusted models for mortality, below-median income (aHR 1.35, 95% CI 1.03–1.76), long distance (aHR 1.42, 95% CI 1.05–1.92), social isolation (aHR 1.38, 95% CI 1.01–1.90), and distance per 10 km farther from the center (aHR 1.08, 95% CI 1.02–1.14) were associated with increased mortality. Compared with no adverse SDOH, 3+ adverse SDOH factors were associated with highest mortality risk (aHR 1.64, 95% CI 1.12–2.40). For progression, below-median income (aHR 1.27, 95% CI 1.00–1.62), social isolation (aHR 1.44, 95% CI 1.01–2.06), and 3+ adverse SDOH factors (aHR 1.47, 95% CI 1.06–2.04) were associated with increased risk. Conclusions: In this real-world lung cancer experience, the cumulative adverse social determinants of health burden were associated with progression and mortality. While individual factors such as geographic distance, lower income, isolation were significant, the cumulative burden had the greatest impact. These results underscore analyzing SDOH as longitudinal and cumulative vulnerability rather than isolated factors and may be transferable across European and American lung cancer care. Multivariable Cox hazard regression model for predictors of mortality/progression. Endpoint aHR 95% CI p-value Death ECOG >=2 1.94 1.43-2.62 <0.001 Stage IV 2.33 1.69-3.21 <0.001 Below-median estimated income 1.35 1.03-1.76 0.032 Long distance to treating center 1.42 1.05-1.92 0.021 Not married/not partnered 1.38 1.01-1.90 0.044 Distance to center, per 10 km 1.08 1.02-1.14 0.007 3+ adverse SDOHs vs 0 1.64 1.12-2.40 0.011 Progression Stage IV 1.78 1.34-2.36 <0.001 Below-median estimated income 1.27 1.00-1.62 0.048 Divorced/separated 1.44 1.01-2.06 0.044 3+ adverse SDOHs vs 0 1.47 1.06-2.04 0.021